Who are Injection Sclerotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Asclera, sclerotherapy with aethoxysclerol foam, talc powder, Talc Slurry Pleurodesis, Varithena®, Polidocanol with Glucose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/injection-sclerotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Injection Sclerotherapy — Competitive Intelligence Brief

Injection Sclerotherapy (Injection Sclerotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sclerosing agent. Area: Vascular/Dermatology.

phase 3 Sclerosing agent Vascular/Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Injection Sclerotherapy (Injection Sclerotherapy) — Gulab Devi Hospital. Injection sclerotherapy works by injecting a sclerosing agent directly into abnormal blood vessels or varicose veins to cause inflammation, fibrosis, and obliteration of the vessel.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Injection Sclerotherapy TARGET	Injection Sclerotherapy	Gulab Devi Hospital	phase 3	Sclerosing agent
Asclera	POLIDOCANOL	Provensis	marketed	Sclerosing Agent [EPC]		2010-01-01
sclerotherapy with aethoxysclerol foam	sclerotherapy with aethoxysclerol foam	Medical University of Vienna	marketed	Sclerosing agent
talc powder	talc powder	Chinese University of Hong Kong	marketed	Sclerosing agent
Talc Slurry Pleurodesis	Talc Slurry Pleurodesis	Memorial Healthcare System	marketed	Sclerosing agent
Varithena®	Varithena®	Boston Scientific Corporation	marketed	Sclerosing agent	Vein endothelium (non-receptor mediated tissue damage)
Polidocanol with Glucose	Polidocanol with Glucose	UPECLIN HC FM Botucatu Unesp	marketed	Sclerosing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sclerosing agent class)

Boston Scientific Corporation · 1 drug in this class
Chinese University of Hong Kong · 1 drug in this class
Gulab Devi Hospital · 1 drug in this class
Imperial College London · 1 drug in this class
Medical University of Vienna · 1 drug in this class
Memorial Healthcare System · 1 drug in this class
UPECLIN HC FM Botucatu Unesp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Injection Sclerotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/injection-sclerotherapy. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab